Ronald Moss

4336118, Jun 22, 1982

Mar 21, 1980

6/131922

James W. Patten - Richland WA
Ronald W. Moss - Richland WA
Edwin D. McClanahan - Richland WA

Battelle Memorial Institute - Richland WA

C23C 1500

204192EC

Methods for improving microstructures of line-of-sight deposited films are described. Columnar growth defects ordinarily produced by geometrical shadowing during deposition of such films are eliminated without resorting to post-deposition thermal or mechanical treatments. The native, as-deposited coating qualities, including homogeneity, fine grain size, and high coating-to-substrate adherence, can thus be retained. The preferred method includes the steps of emitting material from a source toward a substrate to deposit a coating non-uniformly on the substrate surface, removing a portion of the coating uniformly over the surface, again depositing material onto the surface, but from a different direction, and repeating the foregoing steps. The quality of line-of-sight deposited films such as those produced by sputtering, progressively deteriorates as the angle of incidence between the flux and the surface becomes increasingly acute. Depositing non-uniformly, so that the coating becomes progressively thinner as quality deteriorates, followed by uniformly removing some of the coating, such as by resputtering, eliminates the poor quality portions, leaving only high quality portions of the coating.

2016010, Apr 14, 2016

Jun 3, 2014

14/893226

- San Diego CA, US
Ronald D. Moss - Encinitas CA, US

A61K 38/47
A61K 38/18
A61K 9/00

The present disclosure provides novel compositions and methods for treating an infection of the eye resulting from an infection of a member of the Picornavirdae virus family. In particular, the present disclosure provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen, such as a virus. The present disclosure also comprises therapeutic compositions having sialidase activity, including protein based compounds having sialidase catalytic domains. Compounds of the disclosure can be used for treating pathogenic infection to the eye.

6737066, May 18, 2004

May 5, 2000

09/565906

Ronald B. Moss - San Diego CA

The Immune Response Corporation - Carlsbad CA

A61K 3921

4242081, 4241881, 4242781, 536 241

The invention provides immunogenic compositions which enhance -chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing -chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. Also provided is a method of inhibiting AIDS, by enhancing -chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.

2016010, Apr 21, 2016

Jun 10, 2014

14/894918

- San Diego CA, US
Ronald D. Moss - Encinitas CA, US

A61K 38/47
A61K 38/18

The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen.

2016012, May 5, 2016

Jun 10, 2014

14/894896

- San Diego CA, US
Ronald D. Moss - Encinitas CA, US

ANSUN BIOPHARMA, INC. - San Diego CA

A61K 38/47
A61K 38/16

The present disclosure provides novel compositions and methods for treating an infection of the skin resulting from an infection of a member of the virus family. In particular, the present disclosure provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen, such as a virus. The present disclosure also comprises therapeutic compositions having sialidase activity, including protein based compounds having sialidase catalytic domains. Compounds of the disclosure can be used for treating pathogenic infection to the skin.

4468437, Aug 28, 1984

Feb 22, 1982

6/350738

James W. Patten - Richland WA
Ronald W. Moss - Richland WA
Edwin D. McClanahan - Richland WA

Battelle Memorial Institute - Richland WA

B22F 708
C23C 1300

428553

Methods for improving microstructures of line-of-sight deposited films are described. Columnar growth defects ordinarily produced by geometrical shadowing during deposition of such films are eliminated without resorting to post-deposition thermal or mechanical treatments. The native, as-deposited coating qualities, including homogeneity, fine grain size, and high coating-to-substrate adherence, can thus be retained. The preferred method includes the steps of emitting material from a source toward a substrate to deposit a coating non-uniformly on the substrate surface, removing a portion of the coating uniformly over the surface, again depositing material onto the surface, but from a different direction, and repeating the foregoing steps. The quality of line-of-sight deposited films such as those produced by sputtering, progressively deteriorates as the angle of incidence between the flux and the surface becomes increasingly acute. Depositing non-uniformly, so that the coating becomes progressively thinner as quality deteriorates, followed by uniformly removing some of the coating, such as by resputtering, eliminates the poor quality portions, leaving only high quality portions of the coating.

2017011, May 4, 2017

May 29, 2015

15/314782

- San Diego CA, US
Ronald D. MOSS - San Diego CA, US

A61K 38/47
C07K 14/485
C12N 9/24
A61K 9/00

The present disclosure provides novel compositions and methods for treating an infection by Middle East respiratory syndrome coronavirus (MERS-CoV). In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by MERS:CoV.

2017029, Oct 12, 2017

Sep 17, 2015

15/512009

- San Diego CA, US
Ronald D. Moss - Encinitas CA, US

A61K 38/46
C07K 14/485
C12N 9/24
C07K 14/54
C07K 14/705
C07K 14/81
A61K 38/16
C07K 14/52

The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.